Was the Altimmune (ALT) insider share purchase part of an employee stock plan?

Yes, the 4,571 shares were purchased under Altimmune’s 2019 Employee Stock Purchase Plan. The transaction covers the ESPP purchase period from August 1, 2025 through January 31, 2026 and follows plan-based pricing rules.

Altimmune (ALT) Chief Business Officer acquires 4,571 ESPP shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Altimmune, Inc.'s Chief Business Officer, Jordt Raymond M, increased his direct ownership through the company’s employee stock purchase plan. On January 31, 2026, he acquired 4,571 shares of common stock at a price of $3.07 per share under the 2019 Employee Stock Purchase Plan, tied to the purchase period from August 1, 2025 through January 31, 2026. Following this automatic plan-based purchase, he directly holds 70,107 shares of Altimmune common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jordt Raymond M

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, par value $0.0001	4,571	$3.07	$14K

Holdings After Transaction: Common Stock, par value $0.0001 — 70,107 shares (Direct)

Footnotes (1)

These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/02/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jordt Raymond M

(Last)

(First)

(Middle)

910 CLOPPER ROAD

SUITE 201S

(Street)

GAITHERSBURG

20878

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value $0.0001	01/31/2026		A⁽¹⁾		4,571	A	$3.07⁽²⁾	70,107	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026.

2. In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025.

	/s/ Gregory Weaver, as Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Altimmune (ALT) report for Jordt Raymond M?

Altimmune reported that Chief Business Officer Jordt Raymond M acquired 4,571 shares of common stock. The purchase occurred on January 31, 2026 through the company’s 2019 Employee Stock Purchase Plan, increasing his direct holdings to 70,107 shares.

At what price were the new Altimmune (ALT) shares acquired under the ESPP?

The 4,571 Altimmune shares were acquired at $3.07 per share. According to the plan terms, the purchase price equaled 85% of Altimmune’s common stock closing price on August 1, 2025 for that ESPP period.

How many Altimmune (ALT) shares does Jordt Raymond M own after this transaction?

After the reported transaction, Chief Business Officer Jordt Raymond M directly owns 70,107 Altimmune common shares. This figure reflects the addition of 4,571 shares purchased through the 2019 Employee Stock Purchase Plan purchase period ending January 31, 2026.

What is the role of Jordt Raymond M at Altimmune (ALT)?

Jordt Raymond M serves as Chief Business Officer at Altimmune. His status as an officer makes him a reporting person for insider transactions, requiring disclosure of trades like the ESPP share purchase reported on January 31, 2026.

How is the ESPP purchase price determined for Altimmune (ALT) shares?

For this ESPP period, Altimmune set the purchase price at 85% of the August 1, 2025 closing price of its common stock. This discount mechanism defined the $3.07 per share cost for the 4,571 shares acquired by the Chief Business Officer.